Drug Profile

BL 001

Alternative Names: BL-001

Latest Information Update: 18 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Duke University
Developer Bloom Science
Class Antiepileptic drugs; Bacteria; Neuroprotectants; Obesity therapies
Mechanism of Action GABA modulators; Gastrointestinal microbiome modulators; Glutamate agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Dravet syndrome; Obesity
Phase 0 Epilepsy
No development reported Amyotrophic lateral sclerosis

Most Recent Events

08 Mar 2025 Efficacy and adverse event data from a phase I trial in Obesity released by Bloom Science
04 Mar 2025 Bloom Science plans to initiate a phase II trial for Obesity in 2026
20 Jan 2025 Phase-I clinical trials in Obesity (PO), prior to January 2025 (Bloom Science pipeline, January 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com